Dewayne Charleston is a member of PHEN’s Survivor Network who was initially diagnosed with advanced prostate cancer in 2009, and became metastatic castration resistant
Dewayne Charleston travels to Ghana while receiving clinical trial treatment and enjoys his time there, surround by the smiles of children.
in 2021. Despite this serious diagnosis, Charleston persevered by pursuing clinical trials. With PHEN’s assistance, Dewayne accessed the clinical trial SPLASH (NCT04647526) for metastatic castration resistant patients. This was a PHEN supported clinical trial sponsored by Point BioPharma.
With this clinical trial and afterwards, Dewayne took an aggressive approach to his treatments and experienced a great level of success. As such, he was able to continue his active life-style with a visit to Ghana to volunteer at the local schools.
Patient Benefits of Participating in Clinical Trials:
- Clinical trials are additional treatment options
- Clinical trials provide expert medical care
- Patients receive treatment at minimal or no cost
- Patients are among the first to benefit from a new therapy
- Patients will participate in a new treatment discovery